Quick Takeaways
- This page summarizes Roy Galvin's Form 4 filing for HAEMONETICS CORP (HAE).
- 2 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 03 Nov 2022, 16:54.
Roy Galvin - 01 Nov 2022 Form 4 Insider Report for HAEMONETICS CORP (HAE)
- Signature
- /s/ Thomas V. Powers, attorney-in-fact for Mr. Galvin
- Issuer symbol
- HAE
- Transactions as of
- 01 Nov 2022
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 03 Nov 2022, 16:54:38 UTC
- Previous filing
- 17 Oct 2022
- Next filing
- 17 May 2023
- SEC
- View on sec.gov
Quoteable Key Fact
"Roy Galvin filed Form 4 for HAEMONETICS CORP (HAE) on 03 Nov 2022."
What Changed
- Previous filing in this sequence was filed on 17 Oct 2022.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HAE | Common Stock | Award | +2,382 | 2,382 | 01 Nov 2022 | Direct | F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HAE | Non-qualified Stock Option (Right to Buy) | Award | $0 | +5,263 | $0.000000 | 5,263 | 01 Nov 2022 | Common Stock | 5,263 | $83.96 | Direct | F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. |
| F2 | Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
| F3 | Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. |